The Process of Elimination
This article was originally published in Start Up
Incontinence represents a significant unmet medical need for 20 million Americans that suffer from urge incontinence, and 13 million sufferers of stress incontinence. The market is large, growing, and approachable for small device companies--if they can get funding, that is.
You may also be interested in...
Only a third or less of the population that suffers from urge incontinence seeks treatment, and half of the patients that do discontinue treatment because of the unpleasant side effects of orally-administered drugs that are currently on the market. Situs Corp. hopes to improve upon the efficacy of these drugs and avoid side effects by delivering drug directly into the bladder. The company is developing both formulations of drugs for intravesical (in the bladder) delivery as well as a delivery device.
Genyx Medical Inc.'s initial product, Uryx, is a permanent urethral bulking agent for, for example, coughing or laughing.
Dissatisfied with current invasive and complicated surgical techniques for stress urinary incontinence (SUI), the founders of [Surx Inc.] believe they can offer a better approach with a minimally invasive outpatient procedure that uses low power radio frequency (RF) to shrink collagen on the pelvic floor, and return stretched tissues to their normal anatomical position. SUI affects some 6.5 million women in the US, and more than 18 million worldwide